Get the Stockscreener App
90.25
3.14%
2.75
Pre-market:
89.75
-0.50
-0.55%
Arcellx Inc stock is traded at $90.25, with a volume of 356.93K.
It is up +3.14% in the last 24 hours and up +9.93% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$87.50
Open:
$87.55
24h Volume:
356.93K
Relative Volume:
0.69
Market Cap:
$5.01B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-30.18
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+6.58%
1M Performance:
+9.93%
6M Performance:
+38.95%
1Y Performance:
+7.10%
1-Day Range:
$86.84
$90.60
1-Week Range:
$84.54
$90.60
52-Week Range:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
90.25 | 4.85B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
What institutional flow reveals about Arcellx Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com
Arcellx, Inc. $ACLX Shares Sold by Pier Capital LLC - MarketBeat
Signal strength of Arcellx Inc. stock in tech scannersWeekly Earnings Recap & Weekly Top Gainers Trade List - newser.com
Trend analysis for Arcellx Inc. this weekOil Prices & Verified Technical Signals - newser.com
Fresh Analyst Optimism on CAR T-Cell Advances Might Change the Case for Investing in Arcellx (ACLX) - simplywall.st
Will Arcellx Inc. stock split again soon2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Arcellx (ACLX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Using Python tools to backtest Arcellx Inc. strategiesJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Is Arcellx Inc. stock a buy for dividend growthJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - newser.com
Arcellx Insiders Sell US$3.9m Of Stock, Possibly Signalling Caution - 富途牛牛
Canaccord Genuity Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx’s iMMagine-3 Study: A Potential Game-Changer for Multiple Myeloma Treatment - TipRanks
What drives Arcellx Inc stock priceEnergy Sector Updates & Minimal Capital Growth Ideas - earlytimes.in
Will Arcellx Inc. stock benefit from green energy trendsPortfolio Value Summary & Risk Controlled Stock Alerts - fcp.pa.gov.br
Arcellx Advances in Autoimmune Treatment with Anitocabtagene Autoleucel Study - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):